Apogee Therapeutics (APGE) Total Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Current Liabilities data on file, last reported at $33.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $33.0 million, changed 0.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.0 million (changed 0.02% YoY), and the FY2025 annual result was $27.9 million, down 2.29% from the prior year.
• Total Current Liabilities grew to $33.0 million in Q1 2026 per APGE's latest filing, from $27.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $34.0 million in Q3 2025 and troughed at $10.0 million in Q4 2022.
• A 5-year average of $25.5 million and a median of $27.9 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 105.99% in 2023, then retreated 2.29% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $10.0 million in 2022, then jumped by 105.99% to $20.6 million in 2023, then surged by 38.92% to $28.6 million in 2024, then retreated by 2.29% to $27.9 million in 2025, then advanced by 18.08% to $33.0 million in 2026.
• Business Quant data shows APGE's Total Current Liabilities at $33.0 million in Q1 2026, $27.9 million in Q4 2025, and $34.0 million in Q3 2025.